ストックスクリーナーアプリを入手
196.86
3.14%
5.99
プレマーケット:
197.80
0.94
+0.48%
前日終値:
$190.87
開ける：
$193.02
24時間の取引高:
1.22M
Relative Volume:
0.67
時価総額：
$29.78B
収益：
$4.39B
当期純損益:
$853.00M
株価収益率:
35.73
EPS:
5.5097
ネットキャッシュフロー:
$556.00M
1週間 パフォーマンス:
+3.47%
1か月 パフォーマンス:
+19.36%
6か月 パフォーマンス:
+31.00%
1年 パフォーマンス:
+88.18%
1日の値動き範囲:
$192.82
$199.14
1週間の範囲:
$178.88
$199.14
52週間の値動き範囲:
$88.00
$199.14
Illumina Inc Stock (ILMN) Company Profile
Compare ILMN vs TMO, DHR, IDXX, A, NTRA
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
196.86 | 29.78B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | 繰り返されました | Citigroup | Neutral |
| 2025-02-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-02-10 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-02-07 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-11-12 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-10-17 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-08-28 | アップグレード | Argus | Hold → Buy |
| 2024-08-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-08-14 | アップグレード | TD Cowen | Hold → Buy |
| 2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-12-11 | アップグレード | Citigroup | Sell → Neutral |
| 2023-11-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | 開始されました | Bernstein | Underperform |
| 2023-07-05 | 再開されました | JP Morgan | Neutral |
| 2023-01-25 | ダウングレード | Argus | Buy → Hold |
| 2023-01-05 | 開始されました | Scotiabank | Sector Perform |
| 2022-12-12 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-10-04 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Neutral |
| 2022-07-13 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-01-18 | アップグレード | Stifel | Hold → Buy |
| 2022-01-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-03-31 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | 開始されました | Barclays | Underweight |
| 2020-12-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-10-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | ダウングレード | Stifel | Buy → Hold |
| 2020-09-22 | ダウングレード | UBS | Buy → Neutral |
| 2020-09-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-08-07 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-08-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-04-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | 開始されました | Wells Fargo | Underweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Illumina Inc (ILMN) 最新ニュース
Illumina stock trades steady as investors weigh Q1 2026 recovery and gene sequencing demand - Ad-hoc-news.de
Illumina Inc (ILMN) Shares Surge 3.1% -- What GF Score of 72 Tells Investors - GuruFocus
Illumina Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Illumina stock hits 52-week high at 197.49 USD - Investing.com
Illumina stock surges 90% after InvestingPro Fair Value spotted opportunity By Investing.com - Investing.com
Illumina stock holds after a 2025 revenue rebound - Ad-hoc-news.de
Illumina stock trades steady as investors weigh Q1 2026 revenue decline and cost-cutting plan - Ad-hoc-news.de
Is Illumina Inc (ILMN) Overvalued After 4.2% Rally? GF Value Say - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Lobbying Update: $300,000 of ILLUMINA INC. lobbying was just disclosed - Quiver Quantitative
Geraldine Bliss wants parents to ask, “Could it be genetic?” - Illumina
Illumina stock holds as investors await the next report - Ad-hoc-news.de
Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI - Yahoo Finance
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
ILUB Bond Profile — Key Metrics - TradingView
Illumina stock edges higher as investors weigh Q1 2026 results and genomics demand - Ad-hoc-news.de
Wall Street Just Pushed Illumina Targets to $200. Here’s Where the Stock Could Go - TIKR.com
Illumina stock steadies as investors weigh going concern warning and turnaround plan - ad-hoc-news.de
Illumina stock trades on earnings context after recent guidance - ad-hoc-news.de
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate - GlobeNewswire Inc.
Illumina expands Billion Cell Atlas alliance with Formation Bio, adds two other AI drug developers - Bitget
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors - Illumina
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution - Illumina
Illumina (ILMN) Faces German Recall Order Over Element Sequencing Patent Ruling - Yahoo Finance
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Illumina expands Billion Cell Atlas program with new AI drug dev - GuruFocus
Illumina expands Billion Cell Atlas program with new AI drug developers - marketscreener.com
Juno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First - PR Newswire
Illumina appoints new commercial and legal officers By Investing.com - Investing.com Nigeria
Illumina price tries to gather positive momentumForecast today16-07-2026 - Economies.com
(ILMN) Risk Channels and Responsive Allocation - Stock Traders Daily
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Illumina Inc : TD Cowen Raises Target Price t - Moomoo
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - AOL.com
ILMN5886317 Bond Profile — Key Metrics - TradingView
Video: Illumina gets behind the wheel to drive greater results - Illumina
Element Biosciences Prevails in German Patent Case Against Illumina - Business Wire
Illumina, Inc. Stock 12‑Month Price Target Raised to $165.72, Implies 13% Downside - TradingView
Bioinformatics Services Market Set for Strong Growth Driven - openPR.com
Illumina, Inc. Stock 12‑Month Price Target Raised to $162.94, Implies 14% Downside - TradingView
Illumina builds out C-suite with 2 new execs - MedTech Dive
Illumina Inc (ILMN) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Illumina sets July 30 call on second-quarter 2026 results - Stock Titan
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - marketscreener.com
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer - Morgan County Citizen
Genomics Giant Illumina Taps Veteran Life Sciences Lawyer - Law.com
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know - Yahoo Finance
Illumina leads genomics sequencing with 90% mar... - Pluang
Illumina stock steadies as investors weigh core sequencing demand and regulatory overhang - Ad Hoc News
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat (NASDAQ:ILMN) - Seeking Alpha
Illumina Inc (ILMN) 財務データ
収益
当期純利益
現金流量
EPS
3.57%
大文字化:
|
ボリューム (24 時間):